Introduction to Inpulsis Trials

Sentence Examples

Discover more insights into Inpulsis Trials

Keywords frequently search together with Inpulsis Trials

Narrow sentence examples with built-in keyword filters

Inpulsis Trials sentence examples within open label extension

open label extension

Methods Data from patients treated with ≥1 dose of nintedanib 150 mg two times per day or placebo in the 52-week TOMORROW trial and/or its open-label extension; the two 52-week INPULSIS trials and/or their open-label extension, INPULSIS-ON; and a Phase IIIb trial with a placebo-controlled period of ≥6 months followed by open-label nintedanib were pooled.

Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials

open label extension

BACKGROUND We explored the impact of FVC decline on subsequent FVC decline and mortality in the INPULSIS trials of nintedanib in patients with IPF and their open-label extension, INPULSIS-ON.

Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanib.

More open label extension sentences More Sentences

Inpulsis Trials sentence examples within growth factor receptor

growth factor receptor

Nintedanib, a small molecule receptor tyrosine kinase inhibitor (TKI) of platelet‐derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), and vascular endothelial growth factor receptor (VEGFR), has been approved for IPF after phase III INPULSIS trials in 2014.

Gastric perforation related to concurrent use of nintedanib and ramucirumab

More growth factor receptor sentences More Sentences

More Inpulsis Trials sentence examples
10.1183/20734735.0016-2019

The INPULSIS trials evaluated the efficacy and safety of nintedanib versus placebo in 1066 IPF patients with a diffusing capacity of the lung for carbon monoxide (DLCO) of 30–79% of the predicted value [2].

Assessing quality of life of idiopathic pulmonary fibrosis patients: the INSTAGE study

More Inpulsis Trials sentence examples
10.1183/13993003.01797-2018

We investigated the cardiovascular safety of nintedanib using pooled data from the TOMORROW and INPULSIS trials.

Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials

More Inpulsis Trials sentence examples
10.1183/13993003.01655-2018

In post hoc analyses of pooled data from the INPULSIS trials, the treatment effect of nintedanib versus placebo was not influenced by the presence of emphysema (yes versus no) or by FEV1/FVC ratio (≥0.

Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials

Learn more from Inpulsis Trials

Keywords related to Inpulsis

Keywords related to Trials

Inpulsis Trials
Encyclopedia

What is/are Inpulsis Trials?

Inpulsis Trials - The INPULSIS trials evaluated the efficacy and safety of nintedanib versus placebo in 1066 IPF patients with a diffusing capacity of the lung for carbon monoxide (DLCO) of 30–79% of the predicted value [2]. [1] We investigated the cardiovascular safety of nintedanib using pooled data from the TOMORROW and INPULSIS trials. [2] In post hoc analyses of pooled data from the INPULSIS trials, the treatment effect of nintedanib versus placebo was not influenced by the presence of emphysema (yes versus no) or by FEV1/FVC ratio (≥0. [3]

open label extension

Methods Data from patients treated with ≥1 dose of nintedanib 150 mg two times per day or placebo in the 52-week TOMORROW trial and/or its open-label extension; the two 52-week INPULSIS trials and/or their open-label extension, INPULSIS-ON; and a Phase IIIb trial with a placebo-controlled period of ≥6 months followed by open-label nintedanib were pooled. [1] BACKGROUND We explored the impact of FVC decline on subsequent FVC decline and mortality in the INPULSIS trials of nintedanib in patients with IPF and their open-label extension, INPULSIS-ON. [2]

growth factor receptor

Nintedanib, a small molecule receptor tyrosine kinase inhibitor (TKI) of platelet‐derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), and vascular endothelial growth factor receptor (VEGFR), has been approved for IPF after phase III INPULSIS trials in 2014. [1]